Diagonal Bio (Sweden) Performance
| DIABIO Stock | 0.03 0 4.98% |
Diagonal Bio holds a performance score of 6 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 2.23, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Diagonal Bio will likely underperform. Use Diagonal Bio sortino ratio, semi variance, and the relationship between the standard deviation and value at risk , to analyze future returns on Diagonal Bio.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Diagonal Bio AB are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Diagonal Bio sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 3.7 M | |
| Total Cashflows From Investing Activities | -8.6 M |
Diagonal |
Diagonal Bio Relative Risk vs. Return Landscape
If you would invest 2.31 in Diagonal Bio AB on August 30, 2024 and sell it today you would earn a total of 0.74 from holding Diagonal Bio AB or generate 32.03% return on investment over 90 days. Diagonal Bio AB is generating 1.9012% of daily returns and assumes 21.8522% volatility on return distribution over the 90 days horizon. Simply put, majority of traded equity instruments are less risky than Diagonal on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Diagonal Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Diagonal Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Diagonal Bio AB, and traders can use it to determine the average amount a Diagonal Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.087
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | DIABIO | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 21.85 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.9 actual daily | 37 63% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average Diagonal Bio is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Diagonal Bio by adding it to a well-diversified portfolio.
Diagonal Bio Fundamentals Growth
Diagonal Stock prices reflect investors' perceptions of the future prospects and financial health of Diagonal Bio, and Diagonal Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Diagonal Stock performance.
| Return On Equity | -0.52 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (3.67) % | |||
| Current Valuation | 112.69 K | |||
| Shares Outstanding | 34.77 M | |||
| Price To Book | 0.50 X | |||
| Price To Sales | 3.26 X | |||
| Revenue | 407 K | |||
| EBITDA | (11.66 M) | |||
| Book Value Per Share | 2.39 X | |||
| Cash Flow From Operations | (10.94 M) | |||
| Earnings Per Share | (1.83) X | |||
| Total Asset | 36.01 M | |||
About Diagonal Bio Performance
By analyzing Diagonal Bio's fundamental ratios, stakeholders can gain valuable insights into Diagonal Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Diagonal Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Diagonal Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about Diagonal Bio AB performance evaluation
Checking the ongoing alerts about Diagonal Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Diagonal Bio AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Diagonal Bio AB is way too risky over 90 days horizon | |
| Diagonal Bio AB has some characteristics of a very speculative penny stock | |
| Diagonal Bio AB appears to be risky and price may revert if volatility continues | |
| Diagonal Bio AB has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 407 K. Net Loss for the year was (11.66 M) with loss before overhead, payroll, taxes, and interest of (85 K). | |
| Diagonal Bio generates negative cash flow from operations | |
| About 15.0% of the company shares are held by company insiders |
- Analyzing Diagonal Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Diagonal Bio's stock is overvalued or undervalued compared to its peers.
- Examining Diagonal Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Diagonal Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Diagonal Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Diagonal Bio's stock. These opinions can provide insight into Diagonal Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Diagonal Stock analysis
When running Diagonal Bio's price analysis, check to measure Diagonal Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Diagonal Bio is operating at the current time. Most of Diagonal Bio's value examination focuses on studying past and present price action to predict the probability of Diagonal Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Diagonal Bio's price. Additionally, you may evaluate how the addition of Diagonal Bio to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance |